Thomas Charles Merigan M.D.
Publication Details
-
A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation.
N Engl J Med. 1992; (18): 1182-6
Because of the immunosuppression required, heart-transplant recipients frequently have complications caused by cytomegalovirus (CMV), including pneumonia, esophagitis, gastritis, and a syndrome of fever, hepatitis, and leukopenia. We undertook a controlled trial to evaluate the prophylactic administration of ganciclovir to prevent CMV-induced disease after heart transplantation.
Help